FCCC LOGO Faculty Publications
Younes A , Vose JM , Zelenetz AD , Smith MR , Burris HA , Ansell SM , Klein J , Halpern W , Miceli R , Kumm E , Fox NL , Czuczman MS
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
British Journal of Cancer. 2010 Dec;103(12) :1783-1787
Back to previous list
BACKGROUND: We conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor I (TRAIL-RI) in patients with relapsed non-Hodgkin's lymphoma (NHL). METHODS: Forty patients with relapsed or refractory NHL were treated with either 3 or 10mg kg(-1) mapatumumab every 21 days. In the absence of disease progression or prohibitive toxicity, patients received a maximum of six doses. RESULTS: Mapatumumab was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity. Three patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial response. Immunohistochemistry staining of the TRAIL-RI suggested that strong staining in tumour specimens did not appear to be a requirement for mapatumumab activity in FL. CONCLUSIONS: Mapatumumab is safe and has promising clinical activity in patients with FL. British Journal of Cancer (2010) 103, 1783-1787. doi:10.1038/sj.bjc.6605987 www.bjcancer.com Published online 16 November 2010 (C) 2010 Cancer Research UK
Younes, A. Vose, J. M. Zelenetz, A. D. Smith, M. R. Burris, H. A. Ansell, S. M. Klein, J. Halpern, W. Miceli, R. Kumm, E. Fox, N. L. Czuczman, M. S. Nature publishing group London 691md